Top Biotech Companies in Bengaluru (69)
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.
Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.
Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.
A Fortune 500 company, ranked #133 in 2024, with over 22,000 employees worldwide, Arrow guides innovation forward for over 220,000 leading technology manufacturers and service providers. With 2023 sales of $33 billion, Arrow develops technology solutions that improve business and daily life. Arrow.com is the easiest place for innovators to create, make and manage technology.
Arrow Electronics, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is widely positioned at the top tier of global electronic components and enterprise IT distribution, with Fortune 500 scale and high industry rankings. A broad, integrated role across design, supply chain, and deployment in Components and ECS underpins competitive advantage across regions.
Strong Revenue Growth: Sales and segment revenues have re-accelerated across late 2025 and early 2026, with guidance indicating continued year-over-year expansion. Growth is described as broad-based across Global Components and Enterprise Computing Solutions.
Profitability: Earnings and operating margins improved materially alongside the rebound, with both segments contributing to higher operating income. A strategic shift toward higher-margin, value-added and recurring/software-driven offerings aims to improve durability through the cycle.
BrightInsight provides the leading global platform for biopharma and medtech regulated digital health solutions. We are the launch partner companies trust to accelerate time to market for regulated digital health products including apps, algorithms, medical devices, connected combination products, companion diagnostics, and Software as a Medical Device (SaMD). BrightInsight replaces the need for lengthy and complex ‘build from scratch’ implementations....
Stelis Biopharma is a leading, fully integrated biopharmaceutical contract development and manufacturing organization. The powerhouse to progress your biologic products to market as efficiently as possible, we can cater for the entire product lifecycle for our customers for both drug substances and drug products. Our team has deep expertise in product development and manufacturing with comprehensive capabilities from cell line...
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...
Endpoint Clinical, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.
Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.
Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel’s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are...
Cytel's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Private-equity ownership by Astorg and Nordic Capital is positioned as support to accelerate Cytel’s next phase of growth and innovation, signaling access to growth-oriented capital and sponsorship.
Product Line Growth: East Horizon launched as a cloud-based evolution of Cytel’s trial-design software and has continued adding modules through 2025, indicating ongoing investment and expansion of the software offering.
Market Expansion: Multiple acquisitions in 2022–2023 (e.g., Stève Consultants and co.faktor) and an increase in offices from 2021 to 2023 indicate broader geographic coverage and capability expansion, particularly across Europe.
At Sayre Therapeutics, we focus on bringing hitherto unavailable novel medicines, drug-delivery devices, companion diagnostics and diagnostic imaging agents to medical oncologists, surgical oncologists, radiation oncologists, interventional radiologists and rheumatologists.These include, but are not limited to, small molecules, recombinant proteins,monoclonal antibodies (mAbs),drug-delivery devices and diagnostics in Oncology and Immunology.Our business model encompasses Global access / early access programs, Named Patient...
Biofourmis is a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. We are pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
Sitero is a next-generation, site-focused clinical research organization (CRO) for life sciences and institutional research organizations that helps get treatments to market safer and faster through tech-forward services that streamline research. Accelerate your clinical trial, drive compliance and safety, and unlock innovation with access to powerful technology and world-class services. Sitero combines the expertise of a tenured team with a...
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe,...
Catalyzing Innovation in Pharma with Data-driven Digital Products. The idea of DataZymes germinated with the realization that Pharma Commercial teams had few alternatives to the antiquated and inefficient solutions offered by traditional consulting and technology companies. Already a laggard in analytical maturity, the Pharma industry had been facing challenges to adapt to a Big Data world. We saw that the products offered...
Barrix Agro Sciences Pvt Ltd. is a pioneer in developing eco-friendly IPM & IPNM inputs for agriculture and supports and encourages organic farming. We aim at providing healthier living through healthier food by reducing the excessive dependence on harmful pesticides, which is otherwise considered to be the sole means of controlling pests & improving yield. We provide pheromone traps, chromatic...
At Fusion Worldwide, we have spent more than 20 years sourcing electronics components for our customers. We use our supplier network to help resolve supply chain imbalances and keep your business on track. Whether solving for fluctuating pricing or lengthy lead times, Fusion is here to help you and your business pivot and react to changes quickly.
ubilant Biosys Ltd (JBL) offers end-to-end CRDMO solutions in Structural Biology, Computational Chemistry, Medicinal & Synthetic Chemistry, in-vitro and in-vivo Biology, DMPK, Toxicology, Process R&D & Manufacturing to various Biotech & Pharma companies pursuing drug discovery, development and manufacturing. Jubilant Biosys Limited (JBL) is a subsidiary of Jubilant Pharmova, serving the global life sciences, agrochemicals and specialty chemicals industry through...
FRAUD ALERT: Please take note that it has come to our attention that individuals purporting to work for Repligen are reaching out to prospective job applicants using fraudulent email addresses. All legitimate communications from Repligen will be sent from an individual with an email address ending in @repligen.com. If you have any concerns that a communication may be fraudulent and...
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our...
At Clevergene, we are committed to assisting humanity in decrypting genetic codes to facilitate early detection of genetic disorders, personalized therapy, and development of higher-yielding crops or farm animals for a healthier, happier future. Our state-of-the-art genomics laboratories housing latest DNA analysis platforms, combined with a winning team of multidisciplinary experts strengthens our tenacity to decipher deep molecular insights for...
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve...
Avantor's Top Stability & Growth Strengths
Strong Market Position & Advantage: Disclosures describe one of the two largest global lab distributors via VWR with broad reach into research and production labs worldwide and deep embedment in biopharma workflows. This positions the company as a top-tier player in lab distribution and life-science consumables even if not the overall market leader.
Healthy Cash Flow: Recent updates highlight strong free-cash-flow conversion and deleveraging exiting 2024. Management emphasized ongoing cash generation alongside margin improvement.
Cost & Operational Efficiency: Management is executing multi-year cost programs with margin improvement evident in late 2024. Efficiency actions and portfolio focus are intended to support profitability despite uneven demand.


.jpeg)





























